Last fall, ALS researchers at the University of Zurich in Switzerland and the biotech company Mabylon received research grants from both the ALS Association and the Target ALS Foundation. The total amount received was $592,000 and the research project is the development of patient-derived intrabodies for the treatment of ALS.
https://www.mabylon.com/en/Research-at-Mabylon.htm#Pipeline
Intrabody is an unfamiliar term, but it is a type of antibody. As you know, antibodies are proteins produced by the immune system that circulate in the blood and protect the body from bacteria and viruses that invade the body. Intravody, a type of antibody, is also translated as “intracellular antibody. This means that the antibodies work inside the cells of the body. Conventional antibodies act on proteins on the surface of cells, but this intrabody can target proteins inside the cells.
Intrabody therapies, which have been increasingly studied in recent years, hold great promise as a new strategy for more effective approaches to treating incurable diseases such as cancer, HIV, autoimmune diseases, and neurodegenerative diseases including ALS.
Over the years, it has been reported that abnormalities in intracellular proteins, particularly t